Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
about
Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Effective treatment of a highly active antiretroviral regimen through jejunostomy.Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection.
P2860
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
@ast
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
@en
type
label
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
@ast
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
@en
prefLabel
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
@ast
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
@en
P2860
P1476
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
@en
P2093
Charles B Hicks
Susan S Kaplan
P2860
P304
P356
10.1517/14656566.6.9.1573
P407
P577
2005-08-01T00:00:00Z